<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00692146</url>
  </required_header>
  <id_info>
    <org_study_id>D5090C00009</org_study_id>
    <nct_id>NCT00692146</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Effects Single Oral Dose of AZD1386 (Capsaicin)</brief_title>
  <official_title>A Double-Blind, Randomized, Single-Centre, Placebo-Controlled, Crossover Study to Investigate the Effects of a Single Oral Dose of AZD1386 on Intradermal Capsaicin Evoked Pain Symptoms and Heat Sensitivity in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, randomized, single-centre, placebo-controlled, crossover study to investigate
      the effects of a single oral dose of AZD1386 on intradermal capsaicin evoked pain symptoms
      and heat sensitivity in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS, HPT</measure>
    <time_frame>Visit 2-4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>eVAS, HPT, Laser Doppler imaging,WDT, Somedic allodynia</measure>
    <time_frame>Visit 2-4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs, laboratory variables and adverse event each day throughout the study. paper printout ECG and/or digital ECG throughout the study. Pain evoked assessments visit 1-3</measure>
    <time_frame>Visit 1-5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics/Pharmacodynamics</measure>
    <time_frame>Visit 2-4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Capsaicin Evoked Pain</condition>
  <condition>Heat Sensitivity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>36 subjects receiving a specified volume of the active component AZD1386 in a single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>36 subjects receiving a specified volume of placebo in a single dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1386</intervention_name>
    <description>Oral solution fixed dose (95 mg given orally on two occasions)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral solution fixed dose (95 mg given orally on two occasions)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical normal physical findings, including BP, pulse rate &gt;45 bpm, ECG and
             laboratory assessments

          -  Body Mass Index (BMI) of ≥18 to ≤30 kg/m2 and weight of ≥50 to ≤100 kg.

          -  Non-fertile females

        Exclusion Criteria:

          -  History of hypersensitivity, allergy or atopic/skin disease as judged by Investigator.

          -  History of somatic or psychiatric disease/condition, which may interfere with the
             objectives of the study as judged by the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agneta Berg</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca R&amp;D Södertälje</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ingemar Bylesjö</last_name>
    <role>Principal Investigator</role>
    <affiliation>AstraZeneca R&amp;D CPU Karolinska University Hospital, Stockholm</affiliation>
  </overall_official>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2008</study_first_submitted>
  <study_first_submitted_qc>June 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2008</study_first_posted>
  <last_update_submitted>June 5, 2008</last_update_submitted>
  <last_update_submitted_qc>June 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2008</last_update_posted>
  <responsible_party>
    <name_title>Rolf Karlsten, MD, PhD Medical Science Director</name_title>
    <organization>AstraZeneca R&amp;D Södertälje</organization>
  </responsible_party>
  <keyword>Proof of Mechanism</keyword>
  <keyword>Capsaicin evoked pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

